Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-506195-27-00 | EU Trial (CTIS) Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in disease activity will be assessed.
Upadacitinib is currently being investigated for the treatment of NSV. There will be 2 replicate studies running at the same time (Study 1 and Study 2 with periods A and B), an optional exploratory NB-UVB phototherapy study (Study 3), and a re-randomized dose-escalation study (Study 4). In Period A, participants are placed in 1 of 2 groups called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will receive placebo. In Period B, all participants will receive upadacitinib. Approximately 540 adult and adolescent participants with NSV will be enrolled between each main study at around 180 sites worldwide with an option for adult participants who completed Period A of either study and did not achieve T-VASI90 at week 48 while on study drug, to enter Study 3. Participants who failed to achieve T-VASI75 response at week 118 of Study 1 or 2 or at week 70 of Study 3 will be considered for entry into Study 4.
In Studies 1 and 2: Period A, participants will receive oral tablets of upadacitinib or placebo once a day for 48 weeks. In Period B, participants will receive oral tablets of upadacitinib 15 mg once a day for 112 weeks. Participants will be followed up for 30 days. Study 3 participants will receive upadacitinib monotherapy or upadacitinib with Narrow-Band Ultraviolet B (NB-UBV) phototherapy for at least 24 weeks followed by upadacitinib alone. In Study 4, participants will be re-randomized to receive oral tablets of upadacitinib 15 mg or 30 mg once a day for 56 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study 1, Period A: Group 1 | Experimental | Participants will receive upadacitinib 15 mg once daily for 48 weeks. |
|
| Study 1, Period A: Group 2 | Placebo Comparator | Participants will receive placebo once daily for 48 weeks. |
|
| Study 2, Period A: Group 1 | Experimental | Participants will receive upadacitinib 15 mg once daily for 48 weeks. |
|
| Study 2, Period A: Group 2 | Placebo Comparator | Participants will receive placebo once daily for 48 weeks. |
|
| Study 1, Period B: Group 1 Open-Label Extension Period | Experimental | Participants that were randomized to receive upadacitinib in Period A Group 1, will continue to receive upadacitinib 15 mg once daily for 112 weeks in Period B. |
|
| Study 1, Period B: Group 2 Open-Label Extension Period |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Upadacitinib | Drug | Oral Tablets |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100. | Week 48 |
| Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (≥ 75% Improvement in F-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3. | Week 48 |
| Percentage of Participants Achieving T-VASI 75 (≥ 75% Improvement in T-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100. | Study 4 Week 28 |
| Number of Participants with Adverse Events (AEs) | An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving F-VASI 50 (≥ 50% Improvement in F-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3. | Week 48 |
Not provided
Inclusion Criteria:
Documented clinical diagnosis of non-segmented vitiligo (NSV).
At Screening and Baseline Visits, participants must satisfy at least 1 of the following criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Advanced Research Associates - Glendale /ID# 259915 | Glendale | Arizona | 85308 | United States | ||
| Alliance Dermatology and Mohs Center /ID# 259926 |
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Not provided
Not provided
Not provided
Not provided
Not provided
Participants that were randomized to receive placebo in Period A Group 2, will receive upadacitinib 15 mg once daily for 112 weeks in Period B. |
|
| Study 2, Period B: Group 1 Open-Label Extension Period | Experimental | Participants that were randomized to receive upadacitinib in Period A Group 1, will continue to receive upadacitinib 15 mg once daily for 112 weeks in Period B. |
|
| Study 2, Period B: Group 2 Open-Label Extension Period | Experimental | Participants that were randomized to receive placebo in Period A Group 2, will receive upadacitinib 15 mg once daily for 112 weeks in Period B. |
|
| (Optional) Study 3: Open Label Upadacitinib | Experimental | Participants will receive upadacitinib 15 mg once daily for 112 weeks. |
|
| (Optional) Study 3: Open Label Upadacitinib + NB-UVB | Experimental | Participants will receive 15 mg upadacitinib once daily for 112 weeks and Narrow-band ultraviolet B (NB-UVB) for up to 28 weeks. |
|
| Study 4: Upadacitinib 15 mg | Experimental | Eligible participants will be re-randomized to receive upadacitinib 15 mg once daily for 56 weeks. |
|
| Study 4: Upadacitinib 30 mg | Experimental | Eligible participants will be re-randomized to receive upadacitinib 30 mg once daily for 56 weeks. |
|
|
| Placebo | Drug | Oral Tablets |
|
| NB-UVB (narrow-band ultraviolet B) Phototherapy | Other | NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week |
|
| Up to Approximately Week 175 |
| Percentage of Participants Achieving F-VASI 75 (≥ 75% Improvement in F-VASI From Baseline) |
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3. |
| Week 24 |
| Percent Change from Baseline in F-VASI | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3. | Week 24 |
| Percent Change from Baseline in T-VASI | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100. | Week 48 |
| Percentage of Participants Achieving F-VASI 90 (≥ 90% Improvement in F-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3. | Week 48 |
| Percentage of Participants Achieving T-VASI 75 (≥ 75% Improvement in T-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100. | Week 48 |
| Percentage of Participants Achieving 3D Imaging Facial Vitiligo 40 (≥ 40% Reduction in Facial Vitiligo Area Measured by 3D Digital Imaging from Baseline) (Study 1 Only) | 3D imaging will be used to objectively quantify the facial vitiligo area. | Week 48 |
| Percentage of Participants Achieving No Increase from Baseline in T-VASI Among Participants with Actively Progressing Vitiligo at Baseline | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100. | Up to Approximately Week 12 |
| EU/EMA Only: Percentage of Participants Achieving a Physician's Global Impression of Change - Vitiligo (PhGIC-V) of "Much better (1)" | The physician rates the overall change in the patients vitiligo by comparing the severity of vitiligo right now with the severity of vitiligo since the subject started the study treatment. Responses range from 1 = "Much better" to 5 = "Much worse." | Week 48 |
| EU/EMA Only: Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) score of "A lot less noticeable (4)" or "No longer noticeable (5)" | The VNS is a single-item, validated questionnaire used in clinical trials to assess the noticeability of vitiligo lesions following therapy. The item is scored on a 5-point scale: 1 = more noticeable; 2 = as noticeable; 3 = slightly less noticeable; 4 = a lot less noticeable; and 5 = no longer noticeable. A score of 4 or 5 represents treatment success | Week 48 |
| EU/EMA Only: Percentage of Participants Achieving a Patient's Global Impression of Change-Vitiligo (PaGIC-V) of "Much better (1)" | The PaGIC-V asks participants to rate the overall change in their vitiligo by comparing the severity of their vitiligo right now with the severity of their vitiligo since they started the study treatment. Responses range from 1 = "Much better" to 5 = "Much worse." | Week 48 |
| Phoenix |
| Arizona |
| 85032 |
| United States |
| Private Practice - Dr. Tooraj Raoof /ID# 260055 | Encino | California | 91436 | United States |
| University of California Irvine /ID# 260080 | Irvine | California | 92697-1385 | United States |
| Vitiligo & Pigmentation Institute of Southern California /ID# 259970 | Los Angeles | California | 90036-5679 | United States |
| Dermatology Research Associates /ID# 260056 | Los Angeles | California | 90045 | United States |
| Duplicate_Stanford University /ID# 260081 | Redwood City | California | 94063 | United States |
| Integrative Skin Science and Research /ID# 260060 | Sacramento | California | 95815 | United States |
| University of California Davis Health /ID# 260062 | Sacramento | California | 95817 | United States |
| Clinical Trials Research Institute /ID# 259910 | Thousand Oaks | California | 91320-2130 | United States |
| Skin Care Research Boca Raton /ID# 260094 | Boca Raton | Florida | 33486-2269 | United States |
| Apex Clinical Trials /ID# 260096 | Brandon | Florida | 33511 | United States |
| Florida Academic Dermatology Center /ID# 259919 | Coral Gables | Florida | 33134-5755 | United States |
| Direct Helpers Research Center /ID# 259932 | Hialeah | Florida | 33012 | United States |
| Skin Care Research - Hollywood /ID# 260101 | Hollywood | Florida | 33021-6748 | United States |
| Encore Medical Research /ID# 259963 | Hollywood | Florida | 33021 | United States |
| GSI Clinical Research, LLC /ID# 259918 | Margate | Florida | 33063 | United States |
| Life Clinical Trials - N State Rd - Margate /ID# 260097 | Margate | Florida | 33063 | United States |
| Savin Medical Group, LLC /ID# 259968 | Miami Lakes | Florida | 33014 | United States |
| Advanced Clinical Research Institute - Tampa /ID# 260058 | Tampa | Florida | 33607 | United States |
| Encore Medical Research - Weston /ID# 260542 | Weston | Florida | 33331 | United States |
| Cleaver Medical Group Dermatology /ID# 259925 | Dawsonville | Georgia | 30534 | United States |
| DeNova Research /ID# 260611 | Chicago | Illinois | 60610 | United States |
| Indiana University Health University Hospital /ID# 259974 | Indianapolis | Indiana | 46202 | United States |
| Dawes Fretzin /ID# 260068 | Indianapolis | Indiana | 46256 | United States |
| Tufts Medical Center. /ID# 260088 | Boston | Massachusetts | 02111-1552 | United States |
| UMass Memorial Medical Center - Lake Avenue North /ID# 259921 | Worcester | Massachusetts | 01655 | United States |
| Oakland Hills Dermatology /ID# 260602 | Auburn Hills | Michigan | 48326 | United States |
| Great Lakes Research Group - Bay City /ID# 260600 | Bay City | Michigan | 48706 | United States |
| Hamzavi Dermatology - Canton /ID# 260545 | Canton | Michigan | 48187 | United States |
| Clarkston Dermatology /ID# 260069 | Clarkston | Michigan | 48346 | United States |
| Henry Ford Medical Center - New Center One /ID# 260059 | Detroit | Michigan | 48202-3046 | United States |
| Minnesota Clinical Study Center /ID# 260154 | New Brighton | Minnesota | 55112 | United States |
| Vivida Dermatology- Flamingo /ID# 260609 | Las Vegas | Nevada | 89119-5190 | United States |
| Schweiger Dermatology, P.C. /ID# 260152 | New York | New York | 07044-2946 | United States |
| Icahn School of Medicine at Mount Sinai /ID# 259909 | New York | New York | 10029 | United States |
| DermResearchCenter of New York, Inc. /ID# 259906 | Stony Brook | New York | 11790 | United States |
| ClinOhio Research Services /ID# 260300 | Columbus | Ohio | 43213-4440 | United States |
| Oregon Medical Research Center /ID# 259911 | Portland | Oregon | 97201 | United States |
| Oregon Dermatology and Research Center /ID# 259917 | Portland | Oregon | 97210 | United States |
| Medical University of South Carolina /ID# 259916 | Charleston | South Carolina | 29425 | United States |
| Bellaire Dermatology Associates /ID# 260044 | Bellaire | Texas | 77401 | United States |
| Dermatology Treatment and Research Center /ID# 260078 | Dallas | Texas | 75230 | United States |
| Innovative Dermatology - Plano /ID# 260628 | Plano | Texas | 75024 | United States |
| Dermatology Clinical Research Center of San Antonio /ID# 260047 | San Antonio | Texas | 78229 | United States |
| Progressive Clinical Research /ID# 260070 | San Antonio | Texas | 78229 | United States |
| Buenos Aires Skin /ID# 259885 | Ciudad Autonoma de Buenos Aire | Buenos Aires F.D. | 1055 | Argentina |
| Instituto de Neumonologia y Dermatologia /ID# 259888 | Ciudad Autonoma de Buenos Aire | Buenos Aires F.D. | 1425 | Argentina |
| Psoriahue Med Interdisciplinar /ID# 259890 | Ciudad Autonoma de Buenos Aire | Buenos Aires F.D. | 1425 | Argentina |
| Instituto De Investigaciones Clínicas Córdoba /ID# 260371 | Córdoba | Córdoba Province | 5000 | Argentina |
| Sanatorio 9 de Julio /ID# 260245 | San Miguel de Tucumán | Tucumán Province | 4000 | Argentina |
| Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 259889 | Buenos Aires | 1061 | Argentina |
| Cliniques Universitaires UCL Saint-Luc /ID# 259429 | Brussels | Brussels Capital | 1200 | Belgium |
| Grand Hopital de Charleroi - Les Viviers /ID# 259437 | Charleroi | Hainaut | 6280 | Belgium |
| UZ Gent /ID# 259430 | Ghent | Oost-Vlaanderen | 9000 | Belgium |
| CHU de Liege /ID# 259427 | Liège | 4000 | Belgium |
| Ambulatory for Specialized Medical Care-IPSMC-skin and venereal diseases /ID# 259955 | Sofiya | Sofia | 1407 | Bulgaria |
| Diagnostic Consultative Centre (Dcc) - Foкus 5 /ID# 259956 | Sofiya | Sofia | 1463 | Bulgaria |
| Diagnosis - Consult Centre 20 - Sofia /ID# 259953 | Sofiya | Sofia | 1618 | Bulgaria |
| Medical Center Cordis /ID# 259954 | Pleven | 5800 | Bulgaria |
| Dermatology Research Institute - Blackfoot Trail /ID# 261175 | Calgary | Alberta | T2J 7E1 | Canada |
| Dr. Chih-ho Hong Medical Inc. /ID# 260239 | Surrey | British Columbia | V3R 6A7 | Canada |
| Wiseman Dermatology Research /ID# 260236 | Winnipeg | Manitoba | R3M 3Z4 | Canada |
| Brunswick Dermatology Center /ID# 260237 | Fredericton | New Brunswick | R3M 3Z4 | Canada |
| LEADER Research /ID# 260407 | Hamilton | Ontario | L8L 3C3 | Canada |
| Private Practice - Dr. Kim Papp Clinical Research /ID# 260406 | Waterloo | Ontario | N2J 1C4 | Canada |
| Centre de Recherche dermatologique du Quebec Metropolitain /ID# 260241 | Québec | Quebec | G1V 4X7 | Canada |
| Dre Angelique Gagne-Henley M.D. inc. /ID# 260238 | Saint-Jérôme | Quebec | J7Z 7E2 | Canada |
| Beijing Tongren Hospital Affiliated To Capital Medical University /ID# 260919 | Beijing | Beijing Municipality | 100730 | China |
| Dermatology Hospital of Southern Medical University /ID# 260136 | Guangzhou | Guangdong | 510091 | China |
| The Second Affiliated Hospital of Guangzhou Medical University /ID# 259929 | Guangzhou | Guangdong | 510260 | China |
| Renmin Hospital of Wuhan University /ID# 260477 | Wuhan | Hubei | 430060 | China |
| Second Affiliated Hospital of Xian Jiaotong University /ID# 260011 | Xi'an | Shaanxi | 710004 | China |
| The First Affiliated Hospital of Xi'an Jiaotong University /ID# 260340 | Xi'an | Shaanxi | 710061 | China |
| Shandong Dermatological Hospital /ID# 260338 | Jinan | Shandong | 250022 | China |
| Huashan Hospital, Fudan University /ID# 259823 | Shanghai | Shanghai Municipality | 200040 | China |
| Chengdu Second Municipal People's Hospital /ID# 260423 | Chengdu | Sichuan | 610017 | China |
| West China Hospital, Sichuan University /ID# 260624 | Chengdu | Sichuan | 610041 | China |
| Tianjin Medical University General Hospital /ID# 259812 | Tianjin | Tianjin Municipality | 300052 | China |
| First Affiliated Hospital of Kunming Medical University /ID# 260017 | Kunming | Yunnan | 650032 | China |
| Hangzhou Third People'S Hospital /ID# 261005 | Hangzhou | Zhejiang | 310009 | China |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 260626 | Hangzhou | Zhejiang | 310020 | China |
| The First Affiliated Hospital of Wenzhou Medical University /ID# 259822 | Wenzhou | Zhejiang | 325000 | China |
| Chu de Nice-Hopital Larchet Ii /Id# 259442 | Nice | Alpes-Maritimes | 06202 | France |
| Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-Andre /ID# 259443 | Bordeaux | Gironde | 33000 | France |
| CHU Toulouse - Hopital Larrey /ID# 259445 | Toulouse | Haute-Garonne | 31400 | France |
| Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 259446 | Créteil | Paris | 94010 | France |
| HCL - Hopital Edouard Herriot /ID# 259444 | Lyon | Rhone | 69003 | France |
| Universitaetsklinikum Erlangen /ID# 260153 | Erlangen | Bavaria | 91054 | Germany |
| TUM Klinikum rechts der Isar /ID# 260291 | Munich | Bavaria | 81675 | Germany |
| Dermatologie Mahlow /ID# 260148 | Blankenfelde-Mahlow | Brandenburg | 15831 | Germany |
| MVZ Dermatologisches Zentrum Bonn GmbH /ID# 260287 | Bonn | Hesse | 53111 | Germany |
| Universitaetsklinikum Frankfurt /ID# 260288 | Frankfurt am Main | Hesse | 60590 | Germany |
| Fachklinik Bad Bentheim /ID# 260293 | Bad Bentheim | Lower Saxony | 48455 | Germany |
| Universitaetsklinikum Muenster /ID# 260147 | Münster | North Rhine-Westphalia | 48149 | Germany |
| Universitaetsmedizin Mainz /ID# 260151 | Mainz | Rhineland-Palatinate | 55131 | Germany |
| Universitaetsklinikum Carl Gustav Carus Dresden /ID# 260289 | Dresden | Saxony | 01307 | Germany |
| Private Practice - Dr. Abdou Zarzour /ID# 260290 | Halle | Saxony-Anhalt | 06108 | Germany |
| Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 260294 | Berlin | 10117 | Germany |
| DERMA-B Egeszsegugyi es Szolgaltato - Debrecen - Gyepusor Utca /ID# 260072 | Debrecen | 4031 | Hungary |
| Rabin Medical Center. /ID# 260420 | Petah Tikva | Central District | 4941492 | Israel |
| Hadassah Medical Center-Hebrew University /ID# 259849 | Jerusalem | Jerusalem | 91120 | Israel |
| The Chaim Sheba Medical Center /ID# 259851 | Ramat Gan | Tel Aviv | 5265601 | Israel |
| Tel Aviv Sourasky Medical Center /ID# 259850 | Tel Aviv | Tel Aviv | 6423906 | Israel |
| Rambam Health Care Campus /ID# 259852 | Haifa | 3109601 | Israel |
| IRCCS Istituti Fisioterapici Ospitalieri-Istituto Dermatologico San Gallicano /ID# 259771 | Rome | Roma | 00144 | Italy |
| ASST degli Spedali Civili di Brescia /ID# 259772 | Brescia | 25123 | Italy |
| Nagoya City University Hospital /ID# 260551 | Nagoya | Aichi-ken | 467-8602 | Japan |
| Dermatology and Ophthalmology Kume Clinic /ID# 260555 | Sakai-shi | Osaka | 593-8324 | Japan |
| The University of Osaka Hospital /ID# 261285 | Suita-shi | Osaka | 565-0871 | Japan |
| Nippon Medical School Hospital /ID# 260550 | Bunkyo-ku | Tokyo | 113-8603 | Japan |
| Tokyo Medical University Hospital /ID# 260552 | Shinjuku-ku | Tokyo | 160-0023 | Japan |
| Yamagata University Hospital /ID# 260553 | Yamagata | Yamagata | 990-9585 | Japan |
| Yamanashi Prefectural Central Hospital /ID# 260554 | Kofu | Yamanashi | 400-8506 | Japan |
| Bravis Ziekenhuis /ID# 259501 | Bergen op Zoom | North Brabant | 4624 VT | Netherlands |
| Amphia Ziekenhuis /ID# 259696 | Breda | North Brabant | 4818 CK | Netherlands |
| Amsterdam UMC, locatie AMC /ID# 259676 | Amsterdam | North Holland | 1105 AZ | Netherlands |
| Dermodent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski /ID# 259690 | Osielsko | Kuyavian-Pomeranian Voivodeship | 86-031 | Poland |
| Specjalistyczny Gabinet Dermatologiczny Aplikacyjno Badawczy /ID# 260016 | Krakow | Lesser Poland Voivodeship | 30-002 | Poland |
| Malopolskie Centrum Kliniczne /ID# 259686 | Krakow | Lesser Poland Voivodeship | 30-149 | Poland |
| Krakowskie Centrum Medyczne /ID# 261424 | Krakow | Lesser Poland Voivodeship | 31-501 | Poland |
| Klinika Osipowicz & Turkowski sp.z.o.o /ID# 259761 | Warsaw | Masovian Voivodeship | 00-716 | Poland |
| Klinika Ambroziak Dermatologia /ID# 260018 | Warsaw | Masovian Voivodeship | 02-953 | Poland |
| Royalderm Agnieszka Nawrocka /ID# 259691 | Warsaw | Masovian Voivodeship | 02-962 | Poland |
| Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 259753 | Bialystok | Podlaskie Voivodeship | 15-351 | Poland |
| Centrum Medyczne Angelius Provita /ID# 259752 | Katowice | Silesian Voivodeship | 40-615 | Poland |
| Twoja Przychodnia SCM /ID# 259757 | Szczecin | West Pomeranian Voivodeship | 71-434 | Poland |
| Unidade Local de Saude de Coimbra /ID# 259793 | Coimbra | 3000-075 | Portugal |
| Unidade Local de Saude da Regiao de Leiria /ID# 259789 | Leiria | 2410-197 | Portugal |
| Hospital CUF Descobertas /ID# 259788 | Lisbon | 1998-018 | Portugal |
| Unidade Local de Saude de Santo Antonio /ID# 259791 | Porto | 4099-003 | Portugal |
| Santa Cruz Behavioral (SCB) Research Center /ID# 260100 | Bayamón | 00961-6910 | Puerto Rico |
| Dr. Samuel Sanchez PSC /ID# 260090 | Caguas | 00727 | Puerto Rico |
| Mindful Medical Research /ID# 260092 | San Juan | 00918-3756 | Puerto Rico |
| Derma therapy spol /ID# 260838 | Bratislava | Bratislava Region | 851 01 | Slovakia |
| Fakultna nemocnica Trnava /ID# 260164 | Trnava | 917 02 | Slovakia |
| Chungnam National University Hospital /ID# 260917 | Daejeon | Daejeon Gwang Yeogsi | 35015 | South Korea |
| Soon Chun Hyang University Hospital Bucheon /ID# 260836 | Bucheon-si | Gyeonggido | 14584 | South Korea |
| The Catholic University Of Korea St. Vincent's Hospital /ID# 260880 | Suwon | Gyeonggido | 16247 | South Korea |
| Ajou University Hospital - Suwon-si /ID# 260916 | Suwon | Gyeonggido | 16499 | South Korea |
| Kyung Hee University Hospital at Gangdong /ID# 260879 | Seoul | Seoul Teugbyeolsi | 05278 | South Korea |
| Hospital Universitario Germans Trias i Pujol /ID# 259371 | Badalona | Barcelona | 08916 | Spain |
| Hospital Universitario de Getafe /ID# 259376 | Getafe | Madrid | 28905 | Spain |
| Hospital Universitario Quironsalud Madrid /ID# 259377 | Pozuelo de Alarcón | Madrid | 28223 | Spain |
| Hospital Universitario Clinico San Cecilio /ID# 259374 | Granada | 18016 | Spain |
| Grupo Pedro Jaen /ID# 259375 | Madrid | 28006 | Spain |
| Consorci Hospital General Universitario de Valencia /ID# 259372 | Valencia | 46014 | Spain |
| Hospital Clinico Universitario Lozano Blesa /ID# 259373 | Zaragoza | 50009 | Spain |
| ID | Term |
|---|---|
| D014820 | Vitiligo |
| ID | Term |
|---|---|
| D017496 | Hypopigmentation |
| D010859 | Pigmentation Disorders |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000613732 | upadacitinib |
| D010789 | Phototherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided